Heyman Richard A. 4

What Happened Richard A. Heyman, a non-employee director of Enliven Therapeutics (ELVN), was granted a derivative equity award covering 19,234 shares on 2026-02-12. The grant is reported at $0.00 (no cash paid) and is recorded as an award/acquisition rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-12; Form 4 filed 2026-02-17 (appears timely under the SEC two-business-day rule; Feb 16 was a federal holiday).
• Amount: 19,234 derivative shares reported at $0.00.
• Shares owned after transaction: not specified in the provided filing summary.
• Footnote: 100% of the shares subject to the award will vest on the earlier of (i) the first anniversary of the 2026 annual meeting or (ii) the date of the 2027 annual meeting, provided Heyman remains a non-employee director through the applicable vesting date.
• Transaction type: Grant/award (code A) — a compensation-related equity grant, not a purchase or sale.

Context This is a time‑based director compensation award (derivative equity such as options or RSUs) rather than a market purchase or sale. Such grants are routine for board members and reflect compensation arrangements; they do not by themselves indicate the director bought or sold company stock. The award vests only if the director continues service through the vesting date.